Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #172 on RegenoCell Therapeutics, Inc.(fka RCLL)
trading.jeff
05/14/12 2:20 PM
#173 RE: hawkeye612 #172
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F,11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; ... The Registrant is unable to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 within the prescribed period because of a delay in completing the accounting for this period. Final accounting requires additional time to complete and incorporate in the Form 10 Q. Registrant expects to file within the extension period.